PHARMA NEWS

  • Mylan has reached a $465-million settlement with the US government to resolve claims relating to the classification of the ...

  • Valeant Pharmaceuticals International, a specialty pharmaceutical company, reports that the US Food and Drug Administration ...

  • Biocon, a Bangalore, India-based pharmaceutical manufacturer, plans to resubmit its marketing authorization application ...

  • GlaxoSmithKline (GSK) has opened a new £44-million ($57 million) manufacturing plant to support vaccine production in Montrose, ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • Mylan Leads Drug Approval News

    A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Mylan. Editor's ...

  • Peregrine Pharmaceuticals, a Tustin, California-headquartered biopharmaceutical company, has reduced its overall workforce ...

  • Celgene, Sutro Revise ADC Pact

    Sutro Biopharma, a San Francisco, California-headquartered biopharmaceutical company, has revised its previous collaboration ...

  • Pfizer plans to invest $100 million to expand a gene-therapy manufacturing plant in Sanford, North Carolina. Pfizer had ...

  • Sanofi has filed a patent-infringement lawsuit for two patents against Merck & Co. in a federal district court regarding ...

  • Bayer Healthcare Pharmaceuticals has issued a voluntary Class II recall of more than one million (1,067,520) 12-count cartons ...

  • Amgen lost a round in litigation in seeking to defend its product, Epogen (epoetin alfa), a drug to treat anemia associated ...

  • German pharmaceutical regulators have issued a statement of noncompliance of good manufacturing practice (GMP) to Dr. Reddy’s ...

  • SK Capital, a New York, New York-based private investment firm focused on the specialty materials, chemicals and pharmaceuticals ...

  • Valeant Pharmaceuticals International has received a second Complete Response Letter (CRL) from the US Food and Drug Administration ...

  • Mallinckrodt Pharmaceuticals, a specialty pharmaceutical company, has agreed to acquire InfaCare Pharmaceutical, a Trevose, ...

  • Endo International, a specialty pharmaceutical and generic-drug company, reported a second-quarter loss of $1.4 billion ...

  • Ocular Therapeutix, a biopharmaceutical company focused on eye-care products, has announced a restructuring involving employee ...

  • Kite Pharma, a Santa Monica, California-headquartered cell therapy company, has advanced its lead its lead investigational ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Abbvie, J&J, Gilead, ...

  • The European Patent Office (EPO) has issued to Merck KGaA a “Notice of Intention to Grant” a patent application covering ...

  • Emergent BioSolutions, a Gaithersburg, Maryland-headquartered specialty biopharmaceutical company, has formed a licensing ...

  • Takeda Partners in Cardio Drug

    Takeda Pharmaceutical and Cardurion Pharmaceuticals, a newly formed Cambridge, Massachusetts-based biotechnology company ...

  • Merck & Co. plans to purchase from Shire a manufacturing facility for its animal health business in Krems an der Donau, ...

  • Bristol-Myers Squibb (BMS) has agreed to acquire IFM Therapeutics (IFM), a company developing therapies to treat cancer, ...

  • Teva Pharmaceutical Industry has announced plans for a major restructuring involving staff reductions of 7,000 employees ...

  • Seattle Genetics, a Bothell, Washington-headquartered biotechnology company, has agreed to purchase Bristol-Myers Squibb’s ...

  • The European Medicines Agency (EMA) has developed and initiated a business continuity plan to deal with the uncertainty ...

  • Daiichi Sankyo has agreed to settle for $300 million almost 2,300 pending liability lawsuits relating to the company’s olmesartan ...

  • As part of its second-quarter earnings report on July 28, 2017, Merck & Co., provided an update on the impact on its operations ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from AstraZeneca, Bristol-Myers ...

  • A roundup of the latest pipeline news, including from the pharmaceutical majors, featuring news from AstraZeneca, Merck ...

  • Baxter International has completed its previously announced acquisition of Claris Injectables, a generic injectables pharmaceutical ...

  • Alexion Pharmaceuticals, a New Haven, Connecticut-based pharmaceutical company, is redefining its research & development ...

  • Lupin Completes FDA Inspections

    Lupin, a Mumbai, India-headquartered pharmaceutical company, has successfully completed good manufacturing practice (GMP) ...

  • Bristol-Myers Squibb and Clovis Oncology, a Boulder, Colorado-based biopharmaceutical company, have formed a clinical collaboration ...

  • Takeda Pharmaceutical and BioSurfaces, an Ashland, Massachusetts-based biomedical research company, have entered into an ...

  • Takeda Pharmaceutical and Tesaro, a biopharmaceutical company focused on oncology, have formed an exclusive licensing agreement ...

  • Shire and Novimmune, a Geneva, Switzerland-based biopharmaceutical company focused on antibody-based medicines, have entered ...

  • Janssen Pharmaceuticals, part of Johnson & Johnson (J&J), has entered into a worldwide exclusive license and collaboration ...

  • As part of a move to refine its oncology strategy by expanding its investment in new technologies and modalities and reducing ...

  • In two separate moves, Teva Pharmaceutical Industries, Celltrion, an Incheon, Korea-based life-sciences company, Amgen, ...

  • GlaxoSmithKline (GSK) has appointed Karenann Terrell as chief digital and technology officer with a company-wide remit to ...

  • Merck & Co. has launched Renflexis (infliximab-abda), a biosimilar of Johnson & Johnson’s (J&J) anti-inflammatory drug, ...

  • AstraZeneca and Merck & Co. have formed a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s ...

  • Boehringer Ingelheim has announced a $217-million investment to upgrade and expand its Fremont, California manufacturing ...

  • The Executive Board and the Supervisory Board of Stada Arzneimittel AG,a Bad Vibel, Germany-based generic and over-the-counter ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Merck & Co., Gilead ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • Mitsubishi Tanabe Pharma Corporation (MTPC), a subsidiary of Mitsubishi Chemical Holdings Corporation, has agreed to acquire ...

  • Aptevo Therapeutics, Emergent Biosolution’s planned biosciences business spin-off company, and Alligator Bioscience, a biotechnology ...

  • Eli Lilly and Company and Nektar Therapeutics, a biopharmaceutical company, have announced a strategic collaboration to ...

  • Alembic Pharmaceuticals, a Mumbai, India-headquartered pharmaceutical company, has inuagarated  a new manufacturing facility ...

  • Sarepta Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company focused on RNA-targeted therapeutics for ...

  • Sanofi has entered into a research collaboration and global exclusive licensing agreement with Ablynx, a biopharmaceutical ...

  • Endo International, a specialty pharmaceutical and generic-drug company, plans to cease operations and close its manufacturing ...

  • GlaxoSmithKline (GSK) has announced plans to adjust its UK manufacturing network, which includes a potential sale of its ...

  • AstraZeneca plans to invest AU $100 million (US $79.2 million) in its manufacturing operations in Sydney, Australia, which ...

  • Amgen and Array BioPharma, a Boulder, Colorado-based biopharmaceutical company developing small-molecule anti-cancer therapies, ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • Amgen, J&J Lead Drug Approval News

    A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Amgen and J&J. ...

  • Eli Lilly and Company has entered into a settlement agreement with generic companies to resolve pending patent litigation ...

  • The US Food and Drug Administration (FDA) has issued a Complete Response Letter for the biologics license application (BLA) ...

  • Ocular Therapeutix, a biopharmaceutical company focused on eye-disease therapy development, manufacturing, and commercialization, ...

  • Emergent BioSolutions, a specialty biopharmaceutical company, has agreed to acquire ACAM2000, a small-pox vaccine, from ...

  • As part of a move to further pay down debt, Valeant Pharmaceuticals International has agreed to sell its Obagi Medical Products ...

  • A roundup of the latest pipeline news, including from the pharmaceutical majors, featuring news from Novartis and Pfizer. ...

  • Biocon, a Bangalore, India-based pharmaceutical manufacturer, has been cited by French regulatory authorities for GMP deficiencies ...

  • PlantForm, an Ontario, Canada-based biopharmaceutical company, and Rio de Janeiro, Brazil-based   Axis Biotec Brasil, a ...

  • Eli Lilly and Company has received a favorable ruling from the UK Supreme Court regarding patent litigation regarding the ...

  • Eli Lilly and Company and Purdue University have formed a five-year, $52-million strategic collaboration for life-science ...

  • Endo International, a generics and specialty branded pharmaceutical company, has decided to voluntarily remove Opana ER ...

  • Sarepta Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company focused on RNA-targeted therapeutics for ...

  • Endo Completes Two Divestments

    Endo International, a generics and specialty branded pharmaceutical company, has completed its previously announced $100-million ...

  • Shire has obtained a preliminary injunction in a court in Hamburg, Germany against Roche to address what it says are “incomplete ...

  • A roundup of the latest pipeline news, including from the pharmaceutical majors, featuring news from GlaxoSmithKline and ...

  • Nidda Healthcare Holding AG, the acquiring company of Boston-based private investment firm Bain Capital and Cinven Partners, ...

  • Sanofi has agreed to acquire Protein Sciences, a Meriden, Connecticut-based privately held vaccines developer and manufacturer, ...

  • Takeda Pharmaceutical started operations for its newly formed clinical research company, Axcelead Drug Discovery Partners, ...

  • Following the recent closure of the sale of the Seattle-based biotechnology company, Dendreon Pharmaceuticals, Valeant Pharmaceuticals ...

  • Bayer Healthcare and Acura Pharmaceuticals, a Palatine, Illinois-based pharmaceutical company, have terminated a license ...

  • PDS Biotechnology Corporation (PDS), a private immuno-oncology company, has entered a clinical trial collaboration agreement ...

  • Neopharma, a pharmaceutical company headquartered in Abu Dhabi, United Arab Emirates (UAE), has confirmed feasibility plans ...

  • A roundup of the latest drug approval news, including from the pharmaceutical majors, featuring news from Novartis, Johnson ...

  • Celgene Corporation has formed a strategic collaboration with BeiGene, a Beijing, China-headquartered clinical-stage biopharmaceutical ...

  • Novartis has signed an agreement with Oxford BioMedica, a company specializing in gene and cell therapy manufacturing, for ...

  • Seqirus, a developer and manufacturer of influenza vaccines, has produced a cell-based influenza vaccine at commercial scale ...

  • GlaxoSmithKline (GSK) has formed a strategic drug-discovery collaboration with Exscientia, a company specializing in artificial ...

  • Pacira Pharmaceuticals, a specialty pharmaceutical company, has discontinued all future production of DepoCyt in the US ...

  • Sun Pharmaceutical Industries, a Mumbai, India-headquartered pharmaceutical company, and Samsung BioLogics, an Incheon, ...

  • Bayer plans to invest approximately EUR 92 million ($104.7 million) at its production site in Kiel, Germany for its animal-health ...

  • Daiichi Sankyo has decided to discontinue the development in Japan of CHS-0214, an investigational etanercept biosimilar in ...

  • Following a failed $5.6-billion acquisition bid by two investment firms that did not gain shareholder approval, Stada Arzneimittel ...

  • Several companies have advanced biosimilars for blockbluster biologics. The European Commission has approved Sandoz’s Erelzi ...

  • Repligen, a life-sciences company focused on bioprocessing technology, has agreed to merge with privately held Spectrum, ...

  • BASF plans to invest EUR 200 million ($227.6 million) to expand its manufacturing capacity for ibuprofen by building a new ...

  • As part of the US Food and Drug Administration’s (FDA) Drug Competition Action Plan that was announced by FDA Commissioner ...

  • Stada Arzneimittel AG, a Bad Vilbel, Germany-based generic and over-the-counter drug company, reports that the proposed ...

  • Lonza has received all regulatory approvals for its proposed $5.5-billion acquisition of Capsugel, a contract provider of ...

  • Pfizer has broken ground on a research and development and process development facility in Chesterfield, Missouri. The ...

  • Pfizer has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its biologics ...

  • Eli Lilly and Company has completed a $90-million expansion of its Biotechnology Center in San Diego, California. The facility ...

  • Baxter International has signed an agreement with Dorizoe Lifesciences, a contract research and development organization, ...

  • Pfizer and Basilea Pharmaceutica, a Swiss biopharmaceutical company specializing in anti-infective and oncological medicines, ...

  • Novartis, Amgen Lead Pipeline News

    A roundup of the latest pipeline news, including from the pharmaceutical majors, featuring news from Novartis and Amgen ...

  • A roundup of the latest drug approval news, including from the pharmaceutical majors, featuring news from Novartis, Teva, ...

  • Merck KGaA’s corporate venture arm has created iOnctura, an immuno-oncology spin-out company based in Geneva, Switzerland. ...

  • Takeda Pharmaceutical Company has completed the construction of a new EUR-100 million ($111-million) solid-dosage manufacturing ...

  • Hospira, a Pfizer company, is voluntarily recalling multiple lots of sodium bicarbonate for injection and other products ...

  • Johnson & Johnson has completed its previously announced acquisition of Actelion, a Swiss pharmaceutical company specializing ...

  • Bristol-Myers Squibb and SK Biotek Co., Ltd. have signed a definitive purchase agreement to sell Bristol-Myers Squibb’s ...

  • As the UK moves into negotiations with the European Union, a new alliance, the Brexit Health Alliance, has been formed as ...

  • Dr. Reddy’s Labpratories is voluntarily recalling 765,018 cartons of its Zenatane (isotretinoin) capsules, an acne medicine, ...

  • Sawai Pharmaceutical, a Japanese generic pharmaceuticals manufacturer, has completed its previously announced acquisition ...

  • A roundup of the latest pipeline news, including from the pharmaceutical majors, featuring news from Amgen, Allergan, ...

  • The US Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated ...

  • Taiho Pharmaceutical, part of the Japanese pharmaceutical company, Otsuka. broke ground for the construction of a new building ...

  • Basilea Pharmaceutica, a Basel, Switzerland-based pharmaceutical company, has been awarded $54.8 million for two additional ...

  • Innate Pharma SA, a biopharmaceutical company, has signed an agreement with Novo Nordisk  granting Innate Pharma full worldwide ...

  • AbbVie has formed a collaboration with Principia Biopharma, a private, clinical-stage biopharmaceutical company, for the ...

  • Bristol-Myers Squibb is voluntarily recalling one lot of the anticoagulant, Eliquis (apixaban), in 5-mg tablets to the consumer ...

  • Boehringer Ingelheim has formed BI X as an independent subsidiary to focus on digital solutions in healthcare from idea ...

  • AstraZeneca has formed an agreement with Grünenthal, a  pharmaceutical company specializing in treatments for pain, gout ...

  • Valeant Pharmaceuticals International, Inc. has entered into an agreement to sell its iNova Pharmaceuticals business to ...

  • A roundup of the latest drug approval news, including from the pharmaceutical majors, featuring news from Biogen, Bristol-Myers ...

  • A roundup of the latest pipeline news, including from the pharmaceutical majors, featuring news from Amgen and Pfizer ...

  • Merck KGaA has formed a new strategic collaboration F-star, a Cambridge, UK-based biopharmaceutical company,, for the development ...

  • Bristol-Myers Squibb has formed separate research pacts with Novartis, Qiagen, and Seattle Genetics for oncology. In ...

  • Novartis has formed a collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient ...

  • Senator Chuck Grassley (R-Iowa), chairman of the US Senate Judiciary Committee, is pressing for further information regarding ...

  • John T. Hendrickson, chief executive officer (CEO) of Perrigo, announced his forthcoming retirement from the company, 14 ...

  • Takeda Pharmaceutical Company Limited has broken ground for a new production facility at its existing Grange Castle site ...

  • Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health report that the US Food and Drug Administration (FDA) has acknowledged ...

  • Roche, in consultation with the Therapeutic Goods Administration (TGA), the national regulatory authority in Australia, ...

  • MSD, known as Merck & Co., Inc., in the U.S. and Canada, plans to invest EUR 280 million ($313 million) over the next ...

  • Pierre Fabre, a French pharmaceutical company, has agreed to acquire several assets from Igenica Biotherapeutics, a Burlingame, ...

  • Protagonist Therapeutics, a Newark, California-based clinical-stage biopharmaceutical company, has formed a worldwide license ...

  • Merck & Co. Inc. has entered into an exclusive worldwide license agreement with Teijin Pharma for the development, manufacture, ...

  • BMS, Advaxis Form Clinical Pact

    Advaxis, a biopharmaceutical company developing immunotherapies, and Bristol-Myers Squibb have formed a clinical development ...

  • BMS, Array BioPharma Partner

    Array BioPharma, a Boulder, Colorado-based biopharmaceutical company developing small-molecule anti-cancer therapies, and ...

  • A roundup of the latest drug approval news, including from the pharmaceutical majors, featuring news from Novartis, Roche, ...

  • A roundup of the latest pipeline news, including from the pharmaceutical majors, featuring news from Pfizer, Novartis, ...

  • Alexion Pharmaceuticals, a New Haven, Connecticut-based biopharmaceutical company, has made further changes to its executive ...

  • GlaxoSmithKline (GSK) has issued a voluntary Class II recall of 562,883 Ventolin HFA (albuterol sulfate) Inhalation, 90 ...

  • Sun Pharma Advanced Research Company Limited (SPARC), part of Sun Pharmaceutical Industries, has received a Complete Response ...

  • Granules India Ltd., a pharmaceutical manufacturing company will invest $35 million into its wholly owned subsidiary, Granules ...

  • Aduro Biotech, a biopharmaceutical company witht immunotherapy technologies, has expanded its clinical collaboration with ...

  • AstraZeneca has entered into an agreement with Recordati S.p.A, an Italian pharmaceutical company, for the commercial rights ...

  • A roundup of the latest drug approval news, including from the pharmaceutical majors, featuring news, with news from ...

  • Novartis plans to add 350 new positions for biological development and manufacturing in Switzerland while cutting approximately ...

  • Biogen has completed an asset purchase of Phase III candidate, Cirara (intravenous glyburide), a drug to treat a severe ...

  • A roundup of the latest drug pipeline news, including from the pharmaceutical majors, featuring news from Amgen, AstraZeneca, ...

  • Bristol-Myers Squibb (BMS) and Calithera Biosciences, a clinical-stage biotechnology company fdeveloping small-molecule ...

  • Merck KGaA announced that it will remain at its headquarters site in Darmstadt, Germany, and announced a plan to upgrade ...

  • Boehringer Ingelheim and Peking University (PKU) in China have formed a strategic partnership with the aim of jointly advancing ...

  • Boehringer Ingelheim has inaugurated its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park in ...

  • Novartis has exercised its option for an exclusive license with Conatus Pharmaceuticals, a biopharmaceutical company, for ...

  • A roundup of the latest drug approval news, including from the pharmaceutical majors, featuring news, with news from ...

  • Lupin Limited, a Mumbai-based pharmaceutical company, has launched, through a partnership with Eli Lilly and Company, Lilly's ...

  • Teva Pharmaceutical Industries reports that it plans to sell certain non-core assets, including its global women’s health ...

  • A roundup of the latest drug pipeline news, including from the pharmaceutical majors, featuring news from AstraZeneca ...

  • Pfizer has formed an exclusive, global collaboration and license agreement, worth up to $545 million, with Richmond, California-based ...

  • Levena Biopharma Co., Ltd., a subsidiary of San Diego-based Sorrento Therapeutics, a clinical-stage biopharmaceutical company, ...

  • Sandoz, the generics arm of Novartis, has formed a development and commercialization agreement, worth up to $293 million, ...

  • Merck & Co. Inc. has formed a clinical-trial collaboration agreement with Array BioPharma, a pharmaceutical company developing ...

  • Sanofi has formed a strategic research collaboration and license option agreement, worth up to $272 million, for bispecific ...

  • Takeda Pharmaceutical Company Limited has cancelled its planned launch in Japan of Vaxem Hib, a conjugate vaccine to prevent ...

  • Takeda Pharmaceutical Company Limited and GammaDelta Therapeutics Ltd, a portfolio biopharmaceutical company of the investmenty ...

  • Amgen has formed a research collaboration for intracellular biologics with Elasmogen Ltd, an Aberdeen, Scotland-based biopharmaceutical ...

  • AstraZeneca has formed a strategic collaboration with Pieris Pharmaceuticals, a Boston-headquartered clinical-stage biopharmaceutical ...

  • Julphar Gulf Pharmaceutical Industries, a Ras Al Khaimah, United Arab Emirates-headquartered generic pharmaceutical company, ...

  • Dr. Reddy’s Laboratories has received a Form 483 with 11 observations from the US Food and Drug Administration (FDA) for ...

  • Due to an expected shortage of Sanofi’s YF-VAX yellow fever vaccine because of a manufacturing issue with Sanofi Pasteur, ...

  • Novartis in CAR-T Patent Deal

    Novartis has entered into a non-exclusive license agreement with Celyad, a Mont-Saint-Guibert, Belgium-headquartered biopharmaceutical ...

  • Lupin, a Mumbai, India-headquartered generic pharmaceutical company, has received a Form 483 from the US Food and Drug Administration ...

  • GlaxoSmithKline (GSK) is investing $139 million in its biopharmaceutical manufacturing site in Rockville, Maryland to expand ...

  • Shire has entered into an agreement with Parion Sciences, a Durham, North Carolina-headquartered development-stage biopharmaceutical ...

  • Otsuka Pharmaceutical has expanded a collaboration with Akebia Therapeutics, Cambridge, Massachusetts-headquartered biopharmaceutical ...

  • Daiichi Sankyo is making an initial Japanese yen 15 billion ($135 million) investment into three of its manufacturing plants ...

  • Allergan has completed the previously announced  acquisition of Zeltiq Aesthetics, a Pleasanton, California-headquartered ...

  • Divi’s Laboratories has received a Warning Letter from the US Food and Drug Administration (FDA) for its active pharmaceutical ...